Financial Shenanigans

Figures converted from GBP at historical period-end FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

The Forensic Verdict

Reckitt's accounting scores Elevated risk (42/100): the income statement, the cash-flow statement, and the management commentary are not telling the same story this year. FY2025 IFRS operating profit jumped 74% to $5,679m, but $1,677m of that increase is the Essential Home disposal gain sitting inside operating profit, and adjusted operating profit grew only 2.0% ($4,354m → $4,771m, ahead of FX). Operating cash flow fell $267m, free-cash conversion dropped from 91% to 71%, and the recurring "non-recurring" Biofreeze impairment hit for a second straight year ($236m in 2025 after $178m in 2024). None of this is shenanigan-grade — there is no restatement, no auditor qualification, no SEC action — but the gap between adjusted earnings, IFRS earnings, and reported cash is wider than usual at the same time the US securities class action over Mead Johnson NEC litigation is still building. The single data point that would change the grade either way is whether the FY2026 cash-tax burden continues at the FY2025 $1,208m run-rate; if it does, FCF conversion stays mid-60s and adjusted EPS becomes a less useful proxy for owner earnings.

Shenanigans Scorecard

Breeding Ground

Reckitt's governance and incentive architecture is mostly clean by FTSE 100 standards, but four conditions raise the prior probability that financial-statement choices lean optimistic: a reset management cohort, a long-tenured auditor in handover, a compensation plan that explicitly excludes goodwill destruction, and an $21.3bn intangible base that requires recurring judgemental impairment testing.

The combination of (a) a CFO who completed only her first full reporting cycle, (b) a lead audit partner in his first year, (c) a multi-year auditor handover beginning in 2026, and (d) a 2024 strategic reset that justifies "one-off" charges in 2024, 2025, and likely 2026 means the 2024–2026 period concentrates the highest-judgement adjustments under the lowest institutional memory. None of this is misconduct; it is a circumstance that historically correlates with optimistic accounting choices.

The compensation lever that is hardest to ignore is the LTIP ROCE definition. The 2026 plan rules state that "LTIP targets include impairments prior to the start of the performance period" — i.e., goodwill destruction from past M&A is added back to capital employed before testing whether the business is earning a 16.7%–18.7% ROCE. A consumer-staples investor underwriting a 14% reported ROCE should know that the executive team is measured against a more flattering version of the same denominator.

Earnings Quality

Underlying revenue growth is real and modestly accelerating, but reported earnings depend heavily on how a reader handles the disposal gain and the recurring "non-recurring" charges.

The IFRS line oscillates wildly because of large impairments ($6.7bn IFCN in 2019, ongoing IFCN/MJN in 2021, $1.05bn intangibles in 2024, $337m in 2025) and now a +$1,677m disposal gain in 2025. Adjusted operating profit, by contrast, has barely moved in seven years ($3.8bn → $4.8bn, a 2% CAGR in dollar terms, with FX noise). The gap between the two is the single most important number in the file: it captures cumulative capital-allocation cost that management asks investors to set aside.

Biofreeze has now been impaired in two consecutive years for a combined $414m on a CGU that was acquired with the 2017 Mead Johnson deal at a much higher carrying value. Audit committee minutes confirm management challenged but accepted the second write-down on the same brand. A genuine "one-off" does not recur; this one has, and the FY2025 audit committee report explicitly flags MJN itself as facing "evolving regulatory environment" pressure on future cash flows. Goodwill plus intangibles still account for 63% of total assets ($21.3bn of $33.8bn), so a single MJN trigger event would dominate the income statement.

Revenue grew 0.3% (IFRS basis, native currency) while receivables grew 1.6% and inventory shrank 2.9%. DSO held at 54 days, DIO declined from 100 to 97 days. There is no evidence of channel stuffing or aggressive sell-in. This is the cleanest part of the file: the underlying volume and price/mix mechanics in the MD&A reconcile to the balance sheet.

The other earnings-quality concern is what is sitting outside the income statement. Reckitt disclosed in the Q4 transcript that "around GBP200 million of restructuring and separation costs … were offset against Essential Home proceeds" — roughly $269m. That $269m never hit reported earnings or adjusted earnings — it was netted against the $2.92bn disposal consideration. Combined with the $263m of in-period restructuring charges, total cash transformation cost in 2025 is closer to $530m, of which only half is visible in P&L adjusting items.

Cash Flow Quality

Free cash flow tells a less flattering story than adjusted EPS, and management acknowledges as much: FCF conversion fell from 91% to 71%.

CFO/Adjusted Operating Profit fell from 77% to 65% in a single year. Three drivers explain it:

1. Working capital drag of $522m (vs $340m in FY24) — payables released cash less aggressively, reflecting a smaller trading base after Essential Home and the routine consumer-staples seasonality. Negative working capital eased from -$1,757m to -$1,567m.
2. Cash tax of $1,208m (vs $877m in FY24, a 28% jump) — driven by disposal-related tax recycling and prior-year tax-position reassessments unwinding.
3. Cash transformation cost of $268m flowing through CFO (vs $76m in FY24) — the in-period payment of restructuring and separation costs that are excluded from adjusted earnings.

The disposal proceeds of $2,405m sit in investing activities, so they do not flatter operating cash flow — that is correct accounting. But the $1,677m disposal gain does flow through IFRS operating profit, which is why CFO/IFRS Net Income looks weak (0.72x) without the gain being a CFO contributor. The cleaner read is CFO/Adjusted Operating Profit at 65%, which is the number management itself uses (FCF conversion 71% includes capex).

For two consecutive years Reckitt has returned more cash to shareholders than FCF generated ($3.1bn–$3.4bn returned vs $2.3bn–$2.8bn FCF). The shortfall is funded by net debt and, in 2025, by the $2.16bn special dividend paid out of Essential Home proceeds in February 2026. This is not a shenanigan — it is openly disclosed in the cash bridge — but it does mean shareholder returns are temporarily exceeding organic cash generation, and net debt at 1.6x adjusted EBITDA understates the true leverage after the special dividend (closer to 2.0x as Eisenhardt acknowledged on the call).

Metric Hygiene

Reckitt's non-GAAP framework is more aggressive than peers in two specific places: the IFRS-Adjusted earnings gap regularly exceeds $1bn (in either direction), and the LTIP ROCE calculation strips out goodwill impairment.

The single most important non-GAAP signal is also the most visible: the Q4 2025 release headlined "IFRS diluted EPS $6.29 (+129.9%)" alongside "adjusted diluted EPS $4.75 (+1.1%)." The 129.9% figure exists because $1,677m of the $2,202m year-on-year increase in earnings is the disposal gain. A reader who sees the IFRS number first will form an impression of the business that the adjusted number then corrects. That sequencing is legal and well-disclosed, but it is asymmetric — when impairments crushed IFRS earnings in 2019, 2021, and 2024, the same management asked investors to use the adjusted line.

The ROCE adjustment is the more durable concern. Reckitt has impaired roughly $8.6bn of goodwill and intangibles since 2019 ($6.7bn IFCN + $2.7bn 2021 + $357m 2023 + $1.05bn 2024 + $337m 2025). Removing those impairments from the LTIP ROCE denominator means the executive team is incentivised on a capital base that economically has been destroyed. The investor's reported ROCE of 14.1% is itself only modestly flattered, but the LTIP version is materially higher, which is what determines pay.

What to Underwrite Next

Five disclosures will determine whether the Elevated grade tightens or loosens. Watch them in this order through the FY2026 reporting cycle:

1. Cash tax run-rate. FY2025 paid $1,208m. If FY2026 stays above $1,000m, FCF conversion stays in the 60s and adjusted EPS becomes a less reliable proxy for owner earnings. If it normalises to $815m–$880m, the FY2025 spike was disposal-related and the cash story improves.
2. MJN goodwill testing. The Audit Committee explicitly flagged MJN's "evolving regulatory environment" as raising the judgemental nature of estimating future cash flows in March 2026. A third large CGU impairment after Biofreeze (FY24, FY25) would be a signal that the $21.3bn intangible base is structurally over-stated and that "adjusted" earnings have been the wrong reference number.
3. NEC litigation reserves. The $145m total legal provision (FY25) covers Korea HS, NEC, Phenylephrine, the UK Securities Action, and other matters. Watson v Mead Johnson alone produced a $60m verdict in March 2024, and the parallel Gill v Abbott verdict was $495m. If 2026 reserves do not increase materially, either Reckitt has high confidence in the November 2024 defence verdict, or the provision is too small. The US securities class action (filed June 2025, S.D.N.Y.) is the more direct accounting risk because it alleges Reckitt's own disclosures around Enfamil safety were materially false.
4. Trade spend accruals. KPMG's first-year lead partner identified trade spend as a Key Audit Matter; the audit committee's review is described as testing "subsequent utilisation" of the FY24 accrual. If the FY26 disclosure shows the FY25 accrual was over-stated and reversed into income, that is a smoothing red flag. If it was under-stated and topped up, gross margin in FY26 will face a non-mechanical headwind.
5. Capex versus depreciation. Capex jumped 32% in FY25 to $828m (vs depreciation excluding impairments of ~$673m). The MD&A attributes this to MJN regulatory upgrades and Wilson, NC plant readiness in FY27. If capex stays elevated through FY27 without a corresponding lift in MJN volume or margin, the prior years of "lower" maintenance capex were under-investment that flattered FCF.

The signal that would downgrade the grade to Watch (21–40): FY2026 FCF conversion above 80%, no further MJN/Biofreeze impairment, and the US securities action dismissed at the motion-to-dismiss stage. The signal that would upgrade to High (61–80): any restatement of prior-year MJN segment results, a third Biofreeze write-down, or the SDNY court denying a motion to dismiss the RBGLY securities class action with prejudice.

This forensic work should affect valuation framing rather than position size. The accounting risks are real but already partially priced — RKT trades at 9.7x earnings and a 4.5% yield as of April 27, 2026, near multi-year lows. The right haircut is to use adjusted operating profit but apply a 5%–10% discount to it for the "smoothing premium" embedded in adjusted EPS, and to use IFRS-net-of-disposal-gain rather than reported IFRS for any cross-cycle margin comparison. The accounting is not a thesis breaker; it is a reason to require a wider margin of safety and to ignore the IFRS EPS line entirely until 2027 reporting normalises.